TORONTO, Jan. 7 /PRNewswire/ -- DRI Capital (formerly Drug Royalty Corporation Inc.) announced today that it has expanded its investment strategy and has launched a Structured Finance Fund with approximately US$300 million. This hybrid debt and equity fund is focused on providing both revenue producing and late stage life sciences and medical device companies financing for a variety of uses. The fund represents capital committed by both DRI Capital and a consortium of existing and new investors
“The Structured Finance Fund applies our expertise in life sciences investing and leverages our core capabilities in providing capital to companies in exchange for an interest in future revenue streams. This novel approach gives companies a capital raising alternative to PIPEs, mezzanine financing, traditional bank and venture debt and convertibles, during volatile capital markets, as a layer of growth capital,” said Joshua Salisbury, Managing Director of DRI Capital’s two Healthcare Funds. Gordon Winston, Head of the Structured Finance Fund added, “Companies, either public or private, seeking capital for sales force expansion, product launch, acquisitions and general corporate purpose, including working capital should be speaking with us. We are a flexible form of capital that can be customized to meet client needs -- we can offer more attractive terms than competing forms of capital and provide structuring advantages such as more favorable pay-down schedules and longer duration instruments. The advantages we provide as an alternative source of funding are material and we are enthusiastic about the industry interest we have already seen.”
About DRI Capital
DRI Capital is a privately held investment management company, focused on the healthcare industry, with over US$1 billion under management. DRI Capital currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund which is described above.
The Royalty Monetization Fund acquires existing royalty streams at competitive rates from companies, institutions and inventors. DRI Capital is a leader in monetizing royalties, having acquired over US$850 million in royalty-based cash flows on commercialized products. In 2007 alone, DRI Capital has deployed about US$450 million with royalty acquisitions on products such as Enbrel, Flumist, Preotact and PEG-INTRON.
CONTACT: Golnar Khosrowshahi, of DRI Capital, +1-416-324-5707,
gk@dricapital.com
Web site: http://www.drugroyalty.com/